Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer

9Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

A 69-year-old man with castration-resistant prostate cancer (CRPC) received docetaxel and a corticosteroid. After the third cycle of docetaxel administration, he presented with dyspnea, cough, sputum, and fever of 39.2°C. The chest X-ray and chest computed tomography (CT) revealed a diffuse reticulonodular shadow in both lungs, which suggested interstitial pneumonitis. Initially, we used empiric broad-spectrum antibiotics and high-dose corticosteroids. However, his condition progressively became worse and he was transferred to the intensive care unit, intubated, and placed on mechanical ventilation. He died 4 days after hospital admission. Here we report this case of fatal interstitial pneumonitis after treatment with docetaxel for CRPC. We briefly consider docetaxel-induced pneumonitis to make physicians aware of the possibility of pulmonary toxicity so that appropriate treatment can be begun as soon as possible. ©The Korean Urological Association, 2012.

Cite

CITATION STYLE

APA

Min, B. D., Kang, H. W., Kim, W. T., Kim, Y. J., Yun, S. J., Lee, S. C., & Kim, W. J. (2012). Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. Korean Journal of Urology, 53(5), 371–374. https://doi.org/10.4111/kju.2012.53.5.371

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free